Wockhardt has had a roller coaster ride for the past six to seven years. Tracing its trajectory over the past decade, I remembered that till 2006, it used to be like any other pharmaceutical company, doing well both in terms of earnings and stock performance. However, in the pre-Lehman credit bubble, the company entered into some credit derivatives against its FCCB/ECB loans due to bad financial management and landed in CDR, with the stock slipping below ₹100. CDR in India is a blessing in disguise for most borrowers. Wockhardt’s lenders restructured the debt and lowered the interest rate, which gave some relief. In hindsight, it appears that with the promoter (Habil Khorakiwala) not being actively involved in the company’s daily affairs, plus a few leveraged overseas acquisitions and derivative contracts, the company landed in a big financial mess.
My Best Pick 2016
Private portfolio manager Vivek Pandey is backing Wockhardt thanks to its long ANDA pipeline
Summer wine and salad
Kishore Singh - January 19, 2015
The million-dollar question: Is investing a game of luck or skill?
Shankar Sharma - May 04, 2021
Every crisis is an opportunity, if you are on the right side of equities
Samir Arora - May 04, 2021
Viraj Mehta trusts the toughness and bounce of a company that has seen many trials
Viraj Mehta - May 04, 2021
Safir Anand spots a mid-sized company with the right chemistry and catalytic circumstances
Safir Anand - May 07, 2021